Mpx Enjoys Record Monthly Revenue of Cdn$5.2 Million in Arizona

MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) has reported that its managed Arizona assets have recorded their best revenue month in March with sales of cannabis and cannabis concentrates hitting the US$4.0 (CDN$5.2) million mark for the first time.

Maricann Announces Operational Update

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI), is pleased to provide investors with the following Operational Update post the closing of our recent $40MM financing.

Emblem Announces $50 Million Bought Deal

Emblem Corp. (TSX VENTURE:EMC)(TSX VENTURE:EMC.WT) is pleased to announce that it has entered into a letter of engagement with Eight Capital pursuant to which Eight Capital has agreed to purchase 12,195,123 units and 25,000 convertible unsecured debentures of the Company, on a "bought deal" basis

Will New York Finally Consider Legalizing Cannabis This Week?

A panel of lawmakers will now hear testimony from some of the state's most experienced advocates for reform. On Thursday morning, the New York State Assembly Standing Committees on Codes, Health, and Alcohol and Drug Abuse will convene a public hearing to discuss the Marijuana Regulation and Taxation Act (MRTA), aimed to legalize the use, distribution, and production of cannabis for adults aged 21 and over.

Aurora Cannabis Completes Strategic Investment in Micron Waste Technologies

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Micron Waste Technologies Inc. (CSE: MWM, OTC: MICWF, Frankfurt: 7FM2), a developer of proprietary digester solutions for the treatment of organic waste, today announced that Aurora has completed a strategic investment in Micron and that the companies have finalized a collaboration agreement pursuant to which both companies will collaborate on the optimization of Micron's technology for the treatment of organic waste generated in the cultivation and production of cannabis products.

MPX Signs Agreement With Israeli Pharmaceutical Company Panaxia for the Production and Marketing of Pharma-Grade Cannabinoid Products

MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that further to its press release dated August 22, 2017, it has entered into a definitive agreement with Panaxia Pharmaceutical Industries Ltd. through its wholly-owned subsidiary Salus BioPharma Corporation, a company engaged in the business of development and production of pharma grade cannabidiol medicinal products, medicinal preparations and medicinal accessories.